BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

...allergen powder (AR101, arc001, peanut allergy oral immunotherapy (oit)) Tremfya, guselkumab (CNTO 1959) Blincyto, blinatumomab (AMG 103, mt103, MEDI-538) Recarbrio...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

...of bone. It intends to launch more programs from Amgen, including Kyprolis carfilzomib and Blincyto blinatumomab...
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

...as CAR Ts, such as neurotoxicity and cytokine release syndrome. The only approved bispecific, Blincyto blinatumomab...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

...has come with a host of toxicity challenges. The only approved CD3 targeting BiTE, Blincyto blinatumomab...
BioCentury | Feb 27, 2020
Product Development

Amgen banks on speed to maintain edge in two hot cancer spaces

...a bispecific T cell engager (BiTE) over the finish line with FDA approval of Blincyto blinatumomab...
...next-generation bispecifics that get around one of Blincyto’s biggest drawbacks are moving through the clinic. Blincyto’s...
...eIF4E - Eukaryotic translation initiation factor 4E K-Ras (KRAS) Lauren Martz, Senior Editor Blincyto, blinatumomab (AMG 103, mt103, MEDI-538) Amgen...
BioCentury | Jan 23, 2020
Company News

With established foothold in Japan, Amgen takes over JV from Astellas

...in the country: cholesterol-lowering agent Repatha evolocumab, osteoporosis drug Evenity romosozumab-aqqg, and leukemia drug Blincyto blinatumomab...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...bispecific, Blincyto blinatumomab from Amgen Inc (NASDAQ:AMGN), and methods to predict response to the bispecifics. Blincyto...
BioCentury | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

...code for the same amino acids via different codons. Kim pointed to the bispecific Blincyto blinatumomab...
BioCentury | Nov 9, 2019
Product Development

Amgen to accelerate China strategy via BeiGene deal

...being reviewed to treat urothelial carcinoma. The deal gives BeiGene China rights to Amgen’s Blincyto blinatumomab...
...B cell lymphoma (DLBCL) BeiGene has the Phase I/II candidate avadomide and Amgen has Blincyto blinatumomab...
...in Japan. Amgen owned 51% of the JV. Two of the drugs -- Repatha and Blincyto...
BioCentury | Oct 31, 2019
Product Development

Amgen deal gives BeiGene dry powder to grow its own pipeline

...minimum of five to seven years to multiple myeloma drug Kyprolis carfilzomib, leukemia therapy Blincyto blinatumomab...
...space, while Blincyto would give BeiGene the opportunity to market the first BiTE in China. Blincyto...
...Editor Kyprolis (Brand), PR-171 (Compound #), ONO-7057 (Compound #), carfilzomib (Generic), Kyprolis (Other) Blincyto, blinatumomab (AMG 103, mt103, MEDI-538) Xgeva...
Items per page:
1 - 10 of 166